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Summary 
 
Recent reports have shown that the selective dopamine D1-like agonist SKF 83822 
[which stimulates adenylate cyclase, but not phospholipase C] induces prominent behavioral 
seizures in mice, whereas its benzazepine congener SKF 83959 [which stimulates 
phospholipase C, but not adenylate cyclase] does not. To investigate the relative involvement 
of D1 vs D5 receptors in mediating seizures, ethological behavioral topography and cortical 
EEGs were recorded in D1, D5 and DARPP-32 knockout mice in response to a convulsant 
dose of SKF 83822. SKF 83822-induced behavioral and EEG seizures were gene dose-
dependently abolished in D1 knockouts. In both heterozygous and homozygous D5 knockouts, 
the latency to first seizure was significantly increased and total EEG seizures were reduced 
relative to wild-types. The majority (60%) of homozygous DARPP-32 knockouts did not have 
seizures; of those having seizures (40%), the latency to first seizure was significantly 
increased and the number of high amplitude, high frequency polyspike EEG events was 
reduced. In addition, immunoblotting was performed to investigate downstream intracellular 
signalling mechanisms at D1-like receptors following challenge with SKF 83822 and SKF 
83959. In wild-types administered SKF 83822, levels of ERK1/2 and GluR1 AMPA receptor 
phosphorylation increased two-fold in both the striatum and hippocampus; in striatal slices 
DARPP-32 phosphorylation at Thr34 increased five-fold relative to vehicle-treated controls. 
These findings indicate that D1, and to a lesser extent D5, receptor coupling to DARPP-32, 
ERK1/2 and glutamatergic signalling is involved in mediating the convulsant effects of SKF 
83822. 
 
Keywords: Dopamine D1-like receptors; Seizures; Adenylate cyclase; DARPP-32; ERK1/2; 
Knockout  
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1. Introduction 
 
Classical pharmacological approaches and, more recently, studies in gene knockout 
mice have shown that stimulation of dopamine D1-like (D1 and D5) and D2-like (D2L/S, D3 and 
D4) receptors can lower and elevate seizure threshold, respectively (Starr, 1996; Weinshenker 
and Szot, 2002). Interestingly, the ability of selective D1-like agonists to induce seizures 
(DeNinno et al., 1991; Holmes et al., 2001) appears to be critically dependent on their 
intracellular signal transduction coupling. Specifically, the selective D1-like agonist SKF 
83822, which stimulates adenylate cyclase (AC), but not phospholipase C (PLC)-mediated 
phosphoinositide hydrolysis (Undie et al., 1994; Peacock and Gerlach, 2001; Rashid et al., 
2007), induces prominent behavioral seizures in mice (O'Sullivan et al., 2004), whereas its 
benzazepine congener SKF 83959, which stimulates PLC, but not AC (Panchalingam and 
Undie, 2001; Jin et al., 2003; Rashid et al., 2007), does not. Furthermore, induction of 
behavioral seizures following challenge with SKF 83822 is conserved in congenic D5 
knockout mice, indicating that among D1-like receptors, selective D1 receptor coupling to AC 
may be important in seizure susceptibility (O'Sullivan et al., 2005).  
In recent years, it has become apparent that downstream signalling at AC-linked D1-
like receptors is more complex than previously envisaged. Dopamine and cAMP-regulated 
phosphoprotein, Mw 32kDa (DARPP-32) is a signal integration molecule that functions as a 
potent inhibitor of protein phosphatase 1 (PP1) when phosphorylated at Thr34 by protein 
kinase A (PKA) and an inhibitor of PKA when phosphorylated at Thr75 by cyclin-dependent 
kinase 5 (Svenningsson et al., 2004). In addition, it has now been established that DARPP-32-
mediated inhibition of PP1 can also activate extracellular-regulated kinases 1 and 2 (ERK1/2; 
Valjent et al., 2000, 2005; Girault et al., 2007). ERK1/2 are members of the mitogen activated 
protein kinase (MAPK) family and are known to be involved in diverse biological processes, 
 5 
including synaptic plasticity and epileptogenesis (Merlo et al., 2004; Thomas and Huganir, 
2004). Evidence for D1-like receptor linkage to MAPK signalling has recently emerged with 
the finding that dopamine-induced cytotoxicity involves D1 receptor-mediated ERK1/2 
activation (Chen et al., 2004).   
A functional role for dopamine in seizure generation has traditionally received little 
attention, with the majority of research focused on glutamatergic and GABAergic 
mechanisms. However, recent findings that (a) phosphorylation of the AMPA receptor 
subunit GluR1 at Serine 845 is increased in response to DARPP-32-mediated inhibition of 
PP1 (Snyder et al., 2000) and (b) AMPA receptor cell surface expression is up-regulated 
following D1 receptor activation in a PKA-dependent manner (Mangiavacchi and Wolf, 2004) 
demonstrate that dopamine can potentiate excitatory glutamatergic transmission. 
To elaborate the importance of selective AC stimulation in mediating subsets of D1-
like dependent behavior, including seizures, we report the first ethological assessment of SKF 
83822 in D1 knockout mice. Furthermore, to investigate the potential involvement of DARPP-
32 in mediating seizure induction by AC-linked D1-like receptors, the electroencephalogram 
(EEG) profile of SKF 83822 was examined in dopamine D1, D5 and DARPP-32 mutants. 
Finally, immunoblotting has been employed to identify possible roles for ERK1/2 activation 
and functional dopamine-glutamate interactions in these processes. 
 
2. Materials and methods 
 
2.1 Mutant mice 
 
For behavioral and EEG studies, the original F2 hybrid (129 × C57BL/6) strain 
containing the mutated D1 receptor, D5 receptor and DARPP-32 alleles were generated as 
 6 
reported previously (Drago et al., 1994; Fienberg et al., 1998; Hollon et al., 2002). To 
establish congenic lines, heterozygous knockouts of these hybrid D1, D5 and DARPP-32 
strains were backcrossed to wild-type C57BL/6 for 15, 10 and 11 generations, respectively 
(McNamara et al., 2003; Nally et al., 2004; O’Sullivan et al., 2005). Analysis of isolated 
genomic DNA by PCR was used to genotype the progeny of heterozygous D1, heterozygous 
D5 and homozygous DARPP-32 intermatings. For each knockout line, wild-type, 
heterozygous and homozygous knockout littermates of the same generational age from these 
intermatings were used. For biochemical studies, adult male C57BL/6 mice (Charles River, 
Sulzfeld, Germany) weighing 25 – 30 g were used. Mice were housed in groups of five, with 
standard laboratory chow and water available ad libitum, and were maintained at 21 ± 1°C on 
a 12 h/12 h (08:00 on; 20:00 off) light/dark schedule. All efforts were made to minimize the 
number of animals used and their suffering. These studies were approved by the Research 
Ethics Committee of the Royal College of Surgeons in Ireland and the Swedish Animal 
Welfare Agency and were conducted under license from the Department of Health & 
Children in accordance with Irish legislation and European Communities Council Directive 
86/609/EEC for the care and use of experimental animals. 
 
2.2. Behavioral assessment 
 
For evaluation of the SKF 83822-induced ethogram, female homozygous D1 knockout 
and wild-type mice were removed from their home cage and placed individually in clear glass 
observation cages (36 × 20 × 20 cm) with wood shavings as bedding material. Mice were then 
allowed to habituate for a period of 3 h to reduce initially high levels of activity in order to 
optimise detection of agonist-induced stimulatory effects. Immediately following challenge 
with SKF 83822 (0.016 – 2.0 mg/kg s.c.) or vehicle, assessments were carried out using a 
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rapid time-sampling behavioral checklist technique and stereotypy rating scale, as previously 
described (Nally et al., 2004; c, 2006; O'Tuathaigh et al., 2006). For this study, the following 
components of the ethogram are reported: sniffing (flaring of nostrils with movement of 
vibrissae); locomotion (coordinated movement of all four limbs producing a change in 
location); rearing to wall (front paws reaching upwards onto or towards a cage wall while 
standing on hind limbs); total grooming (grooming of any form); intense grooming 
(characteristic, programmed syntax of sequential grooming of the snout and then the face with 
the forepaws, followed by grooming of the hind flank/anogenital region with the snout); 
seizures, characterised as any of the following phases occurring within the 60 min observation 
period: phase 1 = sustained immobility/rigidity; phase 2 = rearing with forepaw myoclonus; 
phase 3 = generalized clonus; phase 4 = tonic-clonic seizure or rapid jumping and wild 
running (Ferraro et al., 1999; McKhann et al., 2003; O'Sullivan et al., 2006); stillness 
(motionless: awake with no behavior evident, or asleep). Under these conditions mice were 
used on two occasions only, separated by a drug-free interval of at least one week; on each 
occasion mice were allocated randomly to one of the various treatment groups. All 
assessments were made by an observer who was unaware of genotype and treatment for each 
animal. 
 
2.3. Electroencephalographic recording 
 
Seizure studies were carried out in a manner similar to that described previously 
(Shinoda et al., 2004). Briefly, for surgical implantation of extradural recording electrodes, 
adult male D1, D5 or DARPP-32 knockouts or wild-types were initially anaesthetised using 
5% isoflurane (Abbott Laboratories, Kent, UK) in O2, placed in a stereotaxic frame and 
maintained under anaesthesia using 1.5% isoflurane in O2. Temperature was maintained 
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normothermic (37 ± 0.5°C) by means of a rectal thermometer and thermostatically controlled 
heating pad (Harvard Apparatus, MA, USA). The scalp was incised and a burr hole drilled in 
the exposed cranium over each hippocampus and the frontal cortex. Bitemporal recording 
electrodes and a frontal reference electrode (Plastics One Inc., VA, USA) were then affixed to 
the skull using dental cement (Kemdent, Wiltshire, UK). Following surgery, animals were 
placed in an incubator (Harvard Apparatus, MA, USA) to recover from anaesthesia before 
being returned to their homecage. 24 - 48 h post-surgery, experimental animals were 
connected to a digital EEG monitoring apparatus (AS40 amplifier system; Grass 
Technologies, RI, USA) and a 30 min baseline EEG was recorded before administration of 
SKF 83822 (2.0 mg/kg s.c.) or vehicle. EEGs were recorded for 1 h post-injection and 
subsequently analysed by a trained observer unaware of genotype or treatment for each 
animal; to ensure delayed seizure events were not present, a 5 h EEG was recorded following 
administration of SKF 83822 for each mutant line on at least one occasion. EEG patterns were 
classified as previously described (Shinoda et al., 2004): type I = baseline recording; type II = 
high frequency (> 1 Hz), low voltage spiking (no behavioral correlate); type III = low 
frequency (< 1 Hz), high voltage spiking (corresponding to a phase 2/3 behavioral seizure 
above); type IV = high frequency, high voltage spiking (corresponding to a phase 4 
behavioral seizure above). 
 
2.4. Tissue extraction procedures 
 
For phosphoprotein determination in whole brain structures, male C57BL/6 mice were 
sacrificed by decapitation at specific time points (15, 30 or 60 min) following challenge with 
SKF 83822 (2.0 mg/kg s.c.) or vehicle and heads immediately immersed in liquid nitrogen for 
6 s. The brains were then removed, and the striatum and hippocampus rapidly dissected on an 
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ice-cold surface, sonicated in 1% sodium dodecyl sulfate and boiled for 10 min. This 
procedure prevents protein phosphorylation and dephosphorylation which occur very rapidly 
post-mortem (Svenningsson et al., 2000). For preparation and incubation of striatal slices, 
male C57BL/6 mice were decapitated and the brains rapidly dissected out on an ice-cold 
surface and cut in 250 µm coronal slices using a Leica VT1000S vibrating blade microtome 
(Leica Microsystems AB, Kista, Sweden). Dorsal striata were dissected out from each slice 
under a microscope. Two striatal coronal slices were randomly placed in individual 5 ml 
polypropylene tubes containing 2 ml of Krebs-Ringer biocarbonate buffer (KRB in mM: NaCl 
118, KCl 4.7, CaCl2 1.3, MgSO4 1.5, KH2PO4 1.2, NaHCO3 25 and glucose 11.7; equilibrated 
with 95% O2, 5% CO2 [v/v], pH 7.3). The samples were incubated at 30°C for two 30 min 
periods, each followed by replacement with 2 ml fresh KRB buffer. Samples were then 
incubated with either SKF 83822 (1µM) or vehicle for 5 min. The reaction was rapidly 
terminated by removing the medium, sonicating the slices in 1% sodium dodecyl sulfate and 
boiling for 10 min. 
 
2.5. Determination of phosphoproteins 
 
Determination of protein phosphorylation was carried out in a manner similar to that 
described previously (Hakansson et al., 2006). Briefly, aliquots (5 µl) of the homogenate were 
used for protein determination using the bicinchoninic acid method (Pierce, Oud Beijerland, 
Netherlands). Equal amounts of protein (30 µg) from each sample were loaded onto 10% 
polyacrylamide gels. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and transferred to either Immobilon-FL transfer membranes (Millipore, MA, 
USA) or polyvinylidine diflouride membranes (Amersham Pharmacia Biotech, Uppsala, 
Sweden), as previously described (Towbin et al., 1979). Membranes were then 
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immunoblotted using affinity-purified polyclonal antibodies that selectively detect phospho-
Ser845-GluR1 (Upstate, NY, USA) or phospho-Thr183/Tyr185-ERK1/2 (Cell Signalling 
Technology, MA, USA), or a monoclonal antibody against phospho-Thr34-DARPP-32 
(Snyder et al., 1992). Antibodies against GluR1 (Upstate, NY, USA), ERK1/2 (Cell 
Signalling Technology, MA, USA) and DARPP-32 (Hemmmings and Greengard, 1986) that 
are not phosphorylation state-specific were used to estimate the total amount of proteins. 
Antibody binding was revealed by either one of the following two techniques. In experiments 
where the ECL immunoblotting detection method was employed, a goat anti-mouse 
horseradish peroxidase-linked IgG (Pierce, Oud Beijerland, Netherlands) was used as a 
secondary antibody and the resulting chemiluminescent signal was detected by 
autoradiography. Quantification of the bands corresponding to the phosphorylated or non-
phosphorylated proteins was by densitometry using NIH Image software (version 1.63). 
Alternatively, detection was performed using fluorescent secondary antibodies (Molecular 
probes, OR, USA and Rockland Immunochemicals, PA, USA). On these occasions, 
quantification of antibody binding was by fluorimetry using a Li-Cor Odyssey infrared 
fluorescent detection system (Li-Cor, NE, USA). 
 
2.6. Drugs 
 
The following drugs were used: SKF 83822 [6-chloro-2,3,4,5-tetrahydro-1-(3-
methylphenyl)-3-(2-propenyl)-1H-3-benzazepine-7,8-diol hydrobromide; Tocris Bioscience, 
Bristol, UK]; SKF 83959 [3-methyl-6-chloro-7,8-dihydroxy-1-(3-methylphenyl)-2,3,4,5-
tetrahydro-1H-3-benzazepine; RBI/SRI/NIMH Chemical Synthesis Program, USA]. SKF 
83822 was dissolved in 0.5% dimethyl sulfoxide and administered subcutaneously into the 
flank in a volume of 4.0 ml/kg; control mice received 0.5% dimethyl sulfoxide alone 
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administered in an identical manner. SKF 83959 was dissolved in distilled water and 
administered subcutaneously into the flank in a volume of 2.0 ml/kg; control mice received 
distilled water alone in an identical manner.   
 
2.7. Data analysis 
 
As described previously (Nally et al., 2004; O'Sullivan et al., 2004, 2006; O'Tuathaigh 
et al., 2006), for specification of the agonist-induced ethogram, the total ‘counts’ for each 
individual behavior were determined as the number of 5 s observation windows in which a 
given behavior was evident, summed over the 3 × 15 min [0 - 15, 20 - 35, 40 - 55] cycle 
periods; data were expressed as means ± SEM. Stereotypy scores were averaged over the 60 
min period and expressed similarly. ‘Counts’ for individual behaviors in relation to agonist 
dose were analysed using ANOVA after square-root transformation followed by Student’s t-
test; stereotypy scores were analysed using the Kruskal-Wallis nonparametric ANOVA 
followed by Mann-Whitney U-test. For determination of protein phosphorylation in whole 
striatum/hippocampus and striatal slices, densitometry values were analysed using ANOVA 
followed by Dunnett’s test and Student’s t-test, respectively.    
 
3. Results 
 
3.1. Ethological response to SKF 83822 in D1 knockouts 
 
On examining 11 female homozygous congenic D1 knockout mice, mean body weight 
(19±1 g, mean age 184±11 days) was reduced (-20%, p < 0.001) relative to 15 female wild-
type controls (23±1 g, mean age 187±8 days). Challenge with SKF 83822 (0.016-2.0 mg/kg) 
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induced prominent behavioral seizures at higher doses in wild-type mice [effect of dose, 
F(4,37) = 15.77, p < 0.001], whereas D1 knockouts did not have behavioral seizures at any 
dose [effect of genotype, F(1,37) = 45.81, p < 0.001; dose × genotype interaction, F(4,37) = 
15.77, p < 0.001] (Fig. 1). Co-stimulation of sniffing [effect of dose, F(4,37) = 3.46, p < 0.05] 
and locomotion [effect of dose, F(4,37) = 5.94, p < 0.001] in wild-type mice was not observed 
in D1 knockout mice [effects of genotype, F(1,37) = 31.77, p < 0.001 and F(1,37) = 60.81, p < 
0.001, respectively]. Among topographies of rearing behavior, a significant increase in 
rearing to wall in wild-types [effect of dose, F(4,37) = 3.00, p < 0.05] was not observed in D1 
knockouts [effect of genotype, F(1,37) = 34.67, p < 0.001]. While SKF 83822 did not induce 
general or syntactic (intense) grooming in wild-types, levels of grooming were elevated in D1 
knockouts at higher doses [effect of genotype, F(1,37) = 18.45, p < 0.001; dose × genotype 
interaction, F(4,37) = 2.89, p < 0.05]. A dose-dependent abolition of stillness in wild-types 
[effect of dose, F(4,37) = 4.50, p < 0.01] was not observed in D1 knockouts [effect of 
genotype, F(1,37) = 22.45, p < 0.001]. The emergence of mild stereotyped behavior in wild-
types at higher doses of SKF 83822 was not observed in D1 knockouts. A comparable 
ethological responsive to SKF 83822 reported here in female wild-types has previously been 
described in males (O'Sullivan et al., 2004). 
 
3.2. SKF 83822-induced EEG profile in D1, D5 and DARPP-32 knockouts 
 
Latency to first seizure, total number of seizures over 60 min and the number of type 
IV seizures following systemic administration of SKF 83822 (2.0 mg/kg) in congenic D1, D5 
and DARPP-32 knockouts are shown in Table 1. Vehicle-treated wild-type or knockout mice 
did not have seizures at any point (data not shown). In wild-type mice for the three knockout 
lines, challenge with SKF 83822 induced polyspike paroxysmal seizure EEG with a mean 
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seizure latency of 19 min; there was a mean of 8 seizures over the 60 min period, of which 
approximately 75% were type IV EEG seizure events. SKF 83822-induced seizures were 
gene dose-dependently and completely abolished in D1 knockouts (p < 0.01) (Fig. 2, Table 1). 
In both heterozygous and homozygous D5 knockouts, latency to first seizure was significantly 
increased (+59%, p < 0.01), with significant reductions in the overall number of seizures (-
75%, p < 0.01) and type IV events (-87%, p < 0.05) in homozygous D5 knockouts relative to 
wild-types. The majority (60%) of homozygous DARPP-32 knockouts did not have seizures; 
of those evidencing seizures (40%), latency to first seizure was significantly increased (+61%, 
p < 0.01), while the overall number of seizures and type IV events were reduced (-80%, p < 
0.05 and -75%, p < 0.05 respectively) relative to wild-types. 
 
3.3. SKF 83822- and SKF 83959-induced protein phosphorylation in the striatum and 
hippocampus  
 
At 15 min post administration of SKF 83822 (2.0 mg/kg s.c.), levels of ERK1/2 
phosphorylation increased 2.5-fold in both the striatum [ERK1, F(3,42) = 7.2, p < 0.001; 
ERK2, F(3,42) = 6.1, p < 0.01] and hippocampus [ERK1, F(3,41) = 8.9, p < 0.001; ERK2, 
F(3,41) = 9.1, p < 0.001] and remained significantly elevated throughout the 60 min 
assessment period (Fig. 3a,b). In contrast, systemic administration of PLC-stimulating SKF 
83959 (2.0 mg/kg) had no effect on ERK1/2 phosphorylation in the striatum (Fig. 3c); 
however, a minor but significant increase in ERK1/2 phosphorylation following challenge 
with SKF 83959 was detected in the hippocampus at 15 and 60 min [ERK1, F(3,21) = 5.6, p 
< 0.01; ERK2, F(3,21) = 4.2, p < 0.05] (Fig. 3d). SKF 83822 also induced prominent GluR1 
AMPA receptor phosphorylation at Ser845 in both the striatum [F(3,42) = 32.3, p < 0.001] 
and hippocampus [F(3,42) = 27.7, p < 0.001] after 15 min and this effect was maintained at 
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subsequent time points (Fig. 4a,b). In contrast, PLC-stimulating SKF 83959 induced only 
modest Ser845 GluR1 phosphorylation in the striatum at later time points [F(3,21) = 4.6, p < 
0.05] and was without effect on basal levels of Ser845 GluR1 phosphorylation in the 
hippocampus (Fig 4C, D). Phosphorylation of DARPP-32 at Thr34 in response to SKF 83822 
was more complex: the scatter plot in Fig. 5b shows up to a two-fold increase in some animals 
yet up to a two-fold decrease in others, resulting in no overall effect of SKF 83822 on mean 
DARPP-32 phosphorylation in the striatum at any time point (Fig. 5a); rather, variance in 
SKF 83822-induced DARPP-32 phosphorylation markedly exceeded that in vehicle-treated 
controls at 15, 30 and 60 min [F(10,11) = 9.9, F(11,11) = 10.1 and F(11,11) = 8.9, 
respectively, each p < 0.001]. However, in striatal slices, a five-fold increase in DARPP-32 
phosphorylation at Thr34 was recorded 5 min post-SKF 83822 administration relative to 
vehicle-treated controls (p < 0.001) (Fig. 5c). In contrast, administration of PLC-stimulating 
SKF 83959 reduced levels of DARPP-32 phosphorylation at Thr34 in the striatum at 
intermediate time points [F(3,21) = 3.3, p < 0.05] relative to vehicle-treated controls (Fig. 5a). 
Due to very low basal levels of DARPP-32 expression in the hippocampus, phosphorylation 
of this protein in response to SKF 83822 and SKF 83959 was not examined. 
 
4. Discussion 
 
Determining the precise functional roles of individual dopamine D1-like receptors has 
been complicated at two levels. Firstly, because of their close structural homology, no 
compounds have yet been developed which bind selectively at D1 vs D5 receptors 
(Waddington et al., 2005). Secondly, multiple intracellular signal transduction coupling at 
each receptor serves to increase their functional diversity (O'Sullivan et al., 2004). The 
availability and detailed characterisation of D1 and D5 receptor knockouts has increased our 
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understanding of the gross functional roles of these receptors (Clifford et al., 1998, 1999; 
McNamara et al., 2003; O'Sullivan et al., 2005; Waddington et al., 2005); however, detailed 
information on the functional correlates of heterogeneous intracellular signalling at individual 
D1-like receptors is needed. The present phenotypic characterisation of the AC-stimulating 
D1-like agonist SKF 83822 in D1 knockout mice addresses this issue by allowing systematic 
comparison with previous studies in our laboratory examining the behavioral effects of the 
PLC-stimulating agonist SKF 83959 in such mutants (McNamara et al., 2003) and both 
compounds in D5 knockout mice (O'Sullivan et al., 2005).  
 Homozygous D1 knockouts are unresponsive to the behavioral effects of SKF 83822 
as indicated by its failure to alter vehicle-treated levels for all topographies of behavior. Non-
response of D1 knockouts to doses of SKF 83822 producing profound phenotypic effects in 
wild-types suggests that, within the D1-like subfamily, stimulation of D1 receptors coupled to 
AC is a fundamental requirement for the actions of this drug. The present finding supports our 
recent observation that behavioral responsiveness to SKF 83822 is essentially conserved in 
homozygous D5 knockouts, with only a modest increase in a discrete topography of 
exploratory rearing encountered (O'Sullivan et al., 2005). As expected, SKF 83822 did not 
readily induce grooming, particularly syntactic intense grooming behavior in either wild-types 
or D1 knockouts (O'Sullivan et al., 2005, 2006). A significant dose × genotype interaction for 
overall levels of grooming at higher doses most likely reflects moderate inhibition of 
grooming in control animals with the emergence of prominent seizures, rather than a dose-
dependent release of this behavior in D1 knockouts per se. Failure of SKF 83822 to induce 
syntactic intense grooming in a manner characteristic of other selective D1-like agonists 
(Waddington et al., 1995), combined with previous reports that the ability of SKF 83959 to 
stimulate intense grooming is reduced in both congenic D1 and D5 knockouts (McNamara et 
al., 2003; O'Sullivan et al., 2005), provides additional evidence that D1-like receptor coupling 
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to PLC (but not AC) is necessary to induce complex syntactic grooming behavior, possibly 
via heterooligomerisation with D2 receptors (O'Sullivan et al., 2004; Rashid et al., 2007).  
A major finding of the present study is that the characteristic induction of behavioral 
seizures following challenge with SKF 83822 is abolished in mice with homozygous deletion 
of the D1 receptor. This finding supports our recent observation that SKF 83822-induced 
behavioral seizures are conserved in D5 receptor knockouts (O'Sullivan et al., 2005) and, 
together with numerous reports that the PLC-stimulating SKF 83959 does not induce seizures 
(Clifford et al., 1999; McNamara et al., 2003; O'Sullivan et al., 2005, 2006), provides strong 
evidence that the ability of certain D1-like agonists to lower seizure threshold (DeNinno et al., 
1991; Starr and Starr, 1993) is critically dependent on selective D1 receptor stimulation of 
AC-mediated signalling transduction cascades. Unlike other selective D1-like agonists, SKF 
83822 induced mildly stereotyped sniffing, locomotion and rearing directed around the 
perimeter of the cage (thigmotaxis) in wild-type but not D1 knockouts. This atypical D1-like 
dependent pattern of behavior coincided with the emergence of seizures, was most prominent 
inter-ictally and was observed in D5 and DARPP-32 knockouts evidencing seizures. Thus, 
atypical stereotypy in response to SKF 83822 may represent idiosyncratic post-ictal 
behavioral stimulation. 
To confirm and elaborate the mechanisms of seizure generation at D1-like receptors 
coupled to AC, cortical EEG recording was used to examine the seizure profile of SKF 83822 
in D1, D5 and DARPP-32 knockouts. Despite the use of congenic mutants throughout, 
differences in the overall number of drug-induced seizures were recorded between wild-types 
for each knockout line. The inherent variability of seizure generation and/or subtle genetic 
heterogeneity between the commercially available inbred C57BL/6 strains used to backcross 
the original hybrid lines in establishing congenicity may have produced this effect (McKhann 
et al., 2003; Mohajeri et al., 2004). Regardless, within each knockout line, clear genotypic 
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differences and a consistent pattern of EEG seizure typology in wild-types were apparent. In 
agreement with our behavioral observations, all SKF 83822-induced EEG seizure events (see 
Materials and Methods) were abolished in homozygous D1 knockouts. Interestingly, the 
ability of SKF 83822 to lower seizure threshold was strongly attenuated in heterozygous D1 
mutants, indicating that gene dosage is integral to the mechanism of seizure generation at D1 
receptors. Unlike homozygous D1 knockouts, the majority of homozygous D5 knockouts did 
evidence type IV EEG seizures; however, the latency to first seizure was significantly 
increased in these mutants. Furthermore, the overall number of EEG seizures (type II-IV; see 
Materials and Methods) were reduced similarly in both heterozygous and homozygous D5 
knockouts, indicating that decreasing the level of D5 receptor expression beyond 50% cannot 
further attenuate seizure responses to SKF 83822. When compared with our previous 
observation that SKF 83822-induced behavioral seizures are conserved in D5 knockouts 
(O’Sullivan et al., 2005), the present findings using EEG which is a more sensitive detector of 
seizure activity than behavioral assessment alone indicate that loss of D5 receptors is 
associated with a substantive but only partial reduction in seizure episodes, with those 
remaining being relatively enriched in type III/IV EEG events. Collectively, these EEG 
findings reveal a modest functional role for the D5 receptor in mediating the convulsant 
effects of SKF 83822 that could not be determined using behavioral assessment alone. Given 
that a limited number of D5 knockouts were available to generate the results reported here, 
more comprehensive EEG studies using SKF 83822 in these mutants are needed to clarify 
further the precise involvement of D5 receptors, relative to D1 receptors, in lowing seizure 
threshold via D1-like receptors.  A modest role for D5 receptors in the mechanisms of seizure 
generation by selective D1-like agonists might be expected given the well established 
preponderance of D1 vs D5 receptor expression in both striatal and cortical brain regions.  
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 It is well established that DARPP-32 is an important integrator of signal transduction 
pathways involving cAMP-dependent activation of PKA in dopaminoceptive neurons 
(Svenningsson et al., 2004, 2005). It was therefore of interest to examine the effects of SKF 
83822 in mice lacking functional DARPP-32. Notably, SKF 83822 was without effect in the 
majority of DARPP-32 knockouts tested, consistent with a major role for DARPP-32 in the 
mechanisms of seizure generation at D1-like receptors; of those which did evidence seizures, 
there was a prolonged latency to first seizure and reductions in the overall number of seizures 
and type IV EEG events. As discussed in relation to D5 receptors, more comprehensive EEG 
studies using SKF 83822 in DARPP-32 knockouts are needed to clarify further the precise 
involvement of DARPP-32 in lowing seizure threshold via D1-like receptors. In order to 
verify that SKF 83822 does indeed modulate the activity of DARPP-32, immunoblotting was 
performed to detect the level of DARPP-32 phosphorylation at Thr34 in whole striatum at 
various time points following systemic administration of the convulsive dose of SKF 83822 
used for EEG studies. Unexpectedly, SKF 83822-induced DARPP-32 phosphorylation varied 
dramatically between animals at each time point. Such variability may be related to the 
seizure status of a given animal at the time of phosphoprotein determination, whereby 
DARPP-32 phosphorylation is elevated in advance of and during EEG seizures and inhibited 
during episodes of post-ictal EEG depression. In support of this hypothesis, a robust five-fold 
increase in SKF 83822-induced DARPP-32 phosphorylation at Thr34 was observed in striatal 
slices, which are insensitive to the effects produced by seizure activity in distal brain regions 
connected to the striatum. Interestingly, the PLC-stimulating agonist SKF 83959 was found to 
inhibit DARPP-32 phosphorylation at Thr34 in the striatum, which may explain its lack of 
convulsant effect. Of note, Rashid and colleagues (2007) have recently reported that SKF 
83959 stimulates PLC and intracellular calcium release by activating D1-D2 heterooligomers 
where it is a full agonist at the D1 receptor and a partial agonist at the D2 receptor; D2 receptor 
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activation inhibits DARPP-32 phosphorylation at Thr34 and is known to be anticonvulsant 
(Bozzi et al., 2000; Svenningsson et al., 2004, 2005). 
In this study, we show that the AC-stimulating agonist SKF 83822, but not the PLC-
stimulating agonist SKF 83959, induces prominent ERK1/2 phosphorylation in both the 
hippocampus and striatum, suggesting that seizure induction at D1-like receptors involves 
AC-dependent activation of ERK1/2 signalling. ERK1/2 are implicated in the modulation of 
dendritic potassium channels in the hippocampus (Watanabe et al., 2002; Yuan et al., 2002). 
In particular, ERK-dependent phosphorylation of the Kv4.2 potassium channel subunit has 
been shown to reduce A-type currents and increase excitability of CA1 pyramidal neurons, an 
effect that could be involved in epileptiform activity (Francis et al., 1997). It has recently been 
reported that ERK signalling at D1 receptors occurs via an AC/PKA/DARPP-32 pathway, as 
the ability of amphetamine to induce ERK activation is absent in DARPP-32 mutants (Valjent 
et al., 2005). It is unclear if a similar mechanism is responsible for ERK1/2 activation in the 
present study; however, the fact that SKF 83822-induced seizures were observed in a small 
number of DARPP-32 knockouts suggests that additional signalling pathways exist which 
permit ERK1/2 activation in response to seizure-producing stimulation of D1-like receptors. 
In this regard, D1 receptor stimulation has been shown to facilitate glutamatergic synaptic 
transmission through the modulation of N-methyl-D-aspartate and AMPA receptor function 
(Levine et al., 1996; Cepeda et al., 1998; Snyder et al., 2000; Mangiavacchi and Wolf, 2004) 
which can, in turn, activate ERK1/2 in a DARPP-32-independent manner (Valjent et al., 
2005; Girault et al., 2007). Our finding that SKF 83822, but not SKF 83959, induces 
prominent phosphorylation of the AMPA receptor subunit GluR1 at Serine 845 suggests that 
similar processes might be responsible, at least in part, for the increase in ERK1/2 
phosphorylation observed here. Given that ERK1/2 activation has recently been observed in 
response to seizure-producing stimuli at non-dopamine receptors (Merlo et al., 2004), it is 
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plausible that ERK1/2 function as coincident detectors of generalised epileptiform activity. 
Although targeted deletion of the ERK2 gene is lethal in utero (Yao et al., 2003; Saba-El-Leil 
et al., 2003), future studies examining the seizure profile of diverse chemoconvulsants, 
including SKF 83822, in ERK1 knockouts (Pages et al., 1999) or in combination with SL327 
(an upstream inhibitor of ERK) may reveal novel strategies for seizure prevention. Given the 
present effects of SKF 83822 on the phosphorylation of DARPP-32, ERK1/2 and GluR1-
AMPA receptor subunits in wild-type mice, a priority for future experiments will be to test 
the hypothesis that phosphorylation of these proteins is reduced in D1/D5 receptor and 
DARPP-32 knockouts receiving a convulsant dose of SKF 83822. Additionally, 
characterising the effects of SKF 83822 in other brain regions related to seizures such as the 
cerebral cortex and on the phosphorylation and expression of individual GABA receptor 
subtypes will be important in elucidating further the precise dopaminergic mechanisms 
involved in seizure generation. 
In conclusion, the present findings, together with previous studies in our laboratory 
(McNamara et al., 2003; O’Sullivan et al., 2005), confirm that discrete elements of D1 
receptor function involve exclusive coupling to AC, while others are mediated by coupling to 
PLC. We have shown that the ability of D1-like receptor stimulation to lower seizure 
threshold involves DARPP-32 and perhaps ERK1/2 activation, possibly via functional 
interaction with glutamatergic signalling. Given well-described species differences in 
response to centrally acting dopamine agonists, the clinical implications of the pre-clinical 
findings reported here remain to be clarified. Regardless, considering the need for improved 
therapeutic strategies in epilepsy, further research evaluating the role of D1 receptor signalling 
in seizure processes is warranted. 
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Figure Legends 
 
Fig. 1. Behavioral phenotype in response to SKF 83822 (0.016-2.0 mg/kg s.c.) or vehicle (V) 
following 3 h of habituation. Data are mean behavioral counts ± SEM over a 60 min period 
for seizures, sniffing, locomotion, rearing to wall, total grooming, intense grooming and 
stillness, with stereotypy scores, for wild-type (n = 6 females, filled columns) and 
homozygous D1 knockout (n = 3-4 females, open columns) mice. *p < 0.05, **p < 0.01, ***p 
< 0.001 vs vehicle-treated wild-type controls. ap < 0.05, bp < 0.01, cp < 0.001 between 
genotypes receiving the same dose. 
 
Fig. 2. Representative EEGs following challenge with SKF 83822 (2.0 mg/kg s.c.). All traces 
were captured during the convulsive phase of the drug (20-60 min post-SKF 83822 injection). 
(a) D1 wild-type mouse demonstrating a type IV EEG seizure (high frequency, high voltage 
spiking), corresponding to a phase 4 behavioral seizure (tonic-clonic seizure or rapid jumping 
and wild running). (b) Heterozygous D1 knockout mouse demonstrating a type II EEG seizure 
(high frequency [> 1 Hz], low voltage spiking; no behavioral correlate). (c) Homozygous D1 
knockout mouse demonstrating no EEG abnormalities in response to SKF 83822. Scale bar = 
4 s. 
 
Fig. 3. SKF 83822 and SKF 83959 exhibit distinct modulatory effects on ERK1/2 
phosphorylation in the striatum and hippocampus. Wild-type C57BL/6 mice were treated with 
either SKF 83822 (a,b) or SKF 83959 (c,d) [both 2.0 mg/kg s.c.] and sacrificed by 
decapitation at various time points (15, 30 or 60 min). Phospho-Thr183/Tyr185-ERK1/2 was 
determined by Western blotting using a phosphorylation state-specific antibody. Upper panels 
show representative autoradiograms. Lower panels show a summary of the data expressed as 
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means ± SEM. (n = 5-12). The amount of phospho-Thr183/Tyr185-ERK1/2 is expressed as a 
percentage of that determined after vehicle administration. *p < 0.05, **p < 0.01 vs vehicle-
treated controls. 
 
Fig. 4. SKF 83822 and SKF 83959 both stimulate phospho-Ser845-GluR1 in the striatum, but 
have distinct effects on GluR1 phosphorylation in the hippocampus. Wild-type C57BL/6 mice 
were treated with either SKF 83822 (a,b) or SKF 83959 (c,d) [both 2.0 mg/kg s.c.] and 
sacrificed by decapitation at various time points (15, 30 or 60 min). Phosphorylation of 
GluR1 at Ser845 was determined by Western blotting using a polyclonal phosphorylation-
state specific antibody. Upper panels show representative autoradiograms. Lower panels show 
a summary of the data expressed as means ± SEM (n = 6-12). The amount of phospho-
Ser845-GluR1 is expressed as a percentage of that determined after vehicle administration. *p 
< 0.05, **p < 0.01 vs vehicle-treated controls. 
 
Fig. 5. Effect of SKF 83822 and SKF 83959 on DARPP-32 phosphorylation at Thr34 in the 
striatum. (a) Determination of DARPP-32 phosphorylation in whole striatum. Wild-type 
C57BL/6 mice were treated with either SKF 83822 or SKF 83959 [both 2.0 mg/kg s.c.] and 
sacrificed by decapitation at various time points (15, 30 or 60 min). Phospho-Thr34-DARPP-
32 was determined by Western blotting using a phosphorylation-state specific antibody. 
Upper panel shows a representative autoradiogram for SKF 83959. Lower panel shows a 
summary of the data expressed as means ± SEM (n = 6-12). The amount of phosphorylated 
DARPP-32 is expressed as percentage of that determined after vehicle administration. *p < 
0.05 vs vehicle-treated controls. (b) Scatter plot of the experiment for SKF 83822 shown in 
(a). (c) Determination of DARPP-32 phosphorylation in striatal slices following 5 min 
incubation in the presence of SKF 83822 (1µM). **p < 0.001 vs vehicle-treated controls. 
